Legal & Strategic Advisory for Private Equity and Pharma

My work starts where the deal is. Legal advice that does not change a decision, close a risk or protect a number is not advice, it is overhead. I work deal-driven, with clear priorities and a strong bias toward execution. That means focusing on what materially affects value and deal certainty. License exposure, IP gaps, change-of-control traps, unresolved litigation, compliance weaknesses, governance deficits. The issues that move price, delay timelines or trigger indemnities. Everything else is noise, and noise is the enemy of clean exits. Exit readiness is not a last-mile exercise. It starts on Day One of ownership, because warranty look-back periods, refinancing disclosures and historical compliance questions reach back five years or more. The earlier a company stops questionable practices, cleans up contracts, secures IP, builds scalable governance and prepares credible risk narratives, the stronger its position will be when the exit window opens. My perspective combines three lenses that rarely sit in one person. The legal lens, grounded in twenty-plus years of pharma practice and ExCom-level in-house leadership. The operational lens, formed by running legal, compliance, IP and risk functions inside a global PE-backed business. And the investor lens, shaped by sitting across the table from sponsors, lenders and buyers during transactions, refinancings and exits. The result is pragmatic, efficient and built for the room it serves: investment committees, ExComs, GCs and management teams who need clear, decision-relevant input rather than theoretical analysis.